曲铎;潘东亮;
QU Duo;PAN Dongliang;General ward Ⅰ,Anshan Central Hospital;Department of Urology Surgery,Peking University Shougang Hospital;

• 1:鞍山市中心医院全科病房一病房
• 2:北京大学首钢医院泌尿外科

摘要(Abstract)：

目的:探讨羟苯磺酸钙治疗糖尿病肾病(DKD)的疗效及对患者血清超敏C反应蛋白(hs-CRP)、同型半胱氨酸(Hcy)水平的影响。方法:82例早期DKD患者随机均分为对照组与观察组,A组口服血管紧张素转化酶抑制剂(ACEI)及血管紧张素受体拮抗剂(ARB)治疗、B组在此基础上联合应用羟苯磺酸钙治疗、疗程12周,选取同期40例健康体检者为对照组;观察对照组及治疗前后早期DKD患者血清Hcy、hs-CRP水平及尿白蛋白排泄率(UAER)。结果:治疗前,两组早期DKD患者UAER及血清Hcy、hs-CRP水平均显著高于对照组,差异有统计学意义(P <0. 05);治疗后,两组早期DKD患者尿UAER及血清Hcy、hs-CRP水平均较治疗前显著降低,且B组降低更加明显,差异有统计学意义(P <0. 05)。结论:羟苯磺酸钙治疗DKD可有效降低血清Hcy、hsCRP水平,并降低尿微量白蛋白水平,延缓肾脏病进展。
Objective: To investigate the efficacy of calcium dobesilate in the treatment of diabetic kidney disease( DKD) and its effect on serum hs-CRP and Hcy. Methods: 82 cases of early DKD patients were randomly divided into group A and group B. Group A was treated with angiotensin converting enzyme inhibitor( ACEI) and angiotensin receptor antagonist( ARB). Group B was treated with calcium dobesilate on that basis,and course of the treatment was 12 weeks. 40 cases of healthy individuals in the same period were selected as the control group. The levels of serum Hcy,hs-CRP and urinary UAER in control group and early DKD patients before and after treatment were compared.Results: Before treatment,UAER and serum Hcy and hs-CRP levels of early DKD groups were significantly higher than those in control group( P < 0. 05). After treatment,UAER and serum Hcy and hsCRP levels of the two groups were significantly lower than those before treatment; the decrease in group B was more obvious,and the difference was statistically significant( P < 0. 05). Conclusion: Calcium dobesilate applied in treatment of early diabetic kidney disease can effectively reduce the level of serum Hcy and hs-CRP,and reduce the level of urinary microalbumin,thus delaying the progress of kidney disease.

关键词(KeyWords)： 糖尿病肾病;羟苯磺酸钙;超敏C反应蛋白;同型半胱氨酸;尿微量白蛋白
diabetic kidney disease;calcium dobesilate;hypersensitive C-reactive protein;homocysteine;urinary microalbumin

Abstract:

Keywords:

基金项目(Foundation): 环境化学与生态毒理学国家重点实验室开放基金项目(KF2011-12)

作者(Authors): 曲铎;潘东亮;
QU Duo;PAN Dongliang;General ward Ⅰ,Anshan Central Hospital;Department of Urology Surgery,Peking University Shougang Hospital;

DOI: 10.19367/j.cnki.1000-2707.2019.03.026

参考文献(References)：

• [1]范文君,祝菁菁,黄韻宇,等.我国糖尿病肾病的流行现状及其危险因素[J].中国慢性病预防与控制,2013,21(6):748-751.
• [2]吴雪怡,李航,文煜冰,等. 2型糖尿病肾病患者肾脏病理改变与预后的临床队列研究[J].中华肾脏病杂志,2014,30(9):650-655.
• [3]张瑶,汪力,高芳,等.阿托伐他汀对糖尿病肾病微炎症状态的影响[J].西部医学,2016,28(2):215-217; 220.
• [4]王燕.早期糖尿病肾病患者血浆D-二聚体、纤维蛋白原、同型半胱氨酸的表达及其临床意义[J].中国医药导报,2015,12(9):81-84.
• [5]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2013年版)[J].中华糖尿病杂志,2014,6(7):447-498.
• [6]YANG W,LU J,WENG J,et al. Prevalence of diabetes among men and womenin China[J]. N Engl J Med,2010,362(12):1090-1101.
• [7]华春芬,王飞,叶小君.成人2型糖尿病危险因素的现况研究[J].浙江预防医学,2015,27(1):25-27; 31.
• [8]黄莹芝,叶山东. 2型糖尿病伴高尿酸血症的相关因素分析[J].中国糖尿病杂志,2014,22(5):445-447.
• [9]卢妙心,朱颖霞,吴莹,等.缬沙坦联合阿托伐他汀治疗早期糖尿病肾病对微量白蛋白尿的影响[J].广东医学,2014,35(23):3735-3736.
• [10]饶毅峰,杨林,杜京涛,等.糖尿病肾病患者尿白蛋白排泄率与肾功能、炎症反应、氧化应激反应的相关性[J].海南医学院学报,2017,23(6):769-772.
• [11]唐岚.叶酸对老年H型高血压患者血浆同型半胱氨酸和hs-CRP水平及心血管事件的影响[J].河北医药,2016,38(7):968-971.
• [12]朱秋良,蒋洪敏,王霞平. NGAL和hs-CRP在2型糖尿病早期肾病诊断的临床价值[J].实用预防医学,2014,21(5):612-614.
• [13]张功和,吴节荣,周猛,等.同型半胱氨酸、胱抑素C和超敏C反应蛋白在动脉粥样硬化中的临床意义[J].国际检验医学杂志,2016,37(20):2818-2819; 2822.
• [14]李文峰,罗骏,袁文金,等.慢性心力衰竭患者血浆同型半胱氨酸水平与肾功能恶化的关系[J].中国老年学杂志,2015,35(21):6107-6108.
• [15]刘小菁,刘永泉.尿毒症患者同型半胱氨酸及超敏C反应蛋白水平分析[J].山西医药杂志,2016,45(6):677-678.
• [16]肖丹丹,陶珍珍,诸葛欣.中年男性血清同型半胱氨酸水平与肾小球滤过率变化的关系[J].中华保健医学杂志,2016,18(6):470-473.
• [17]季中秋.羟苯磺酸钙联合缬沙坦对老年早期糖尿病肾病患者血清内皮素和胱抑素C的影响[J].实用临床医药杂志,2015,19(1):39-41.
• [18]王钧.羟苯磺酸钙治疗早期糖尿病肾病的疗效观察[J].中国实用医药,2016,11(22):133-134; 135.
• [19]ALDA O,VALERO M S. PEREBOOM D,et al. In vitro effect of calcium dobesilate on oxidative/inflammatory stress in human varicose veins[J]. Phlebology,2011,26(8):332-337.

文章评论(Comment)：